New drug MT-303 takes on advanced liver cancer in first human trial

NCT ID NCT06478693

Recruiting now Disease control Sponsor: Myeloid Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new drug called MT-303, alone or with two standard cancer drugs, in people with advanced liver cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see early signs of effectiveness. About 70 adults with a specific protein (GPC3) on their cancer cells will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MT-303 (a type of immunotherapy) alone or combined with atezolizumab and bevacizumab
What this could lead to: If it works, this could point toward a new treatment option for advanced liver cancer that has stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 70 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects, and it is too soon to know if it will work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms Simpson-Golabi-Behmel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Cha University Bundang Medical Center
RECRUITING

Gyeonggi-do, South Korea
Integrated Clinical Oncology Network (ICON) Pty Ltd
RECRUITING

Woolloongabba, Queensland, 4102, Australia
Linear Clinical Research
RECRUITING

Murdoch, Western Australia, 6150, Australia
National Taiwan University Hospital
RECRUITING

Taipei, Taiwan
Pusan National Univesity Hospital
RECRUITING

Busan, South Korea
Seoul National University Hospital
RECRUITING

Seoul, South Korea
St Vincent's Hospital
RECRUITING

Sydney, New South Wales, 2010, Australia
Taipei Tzu Chi Hospital
RECRUITING

Taipei, Taiwan
The Alfred Hospital
RECRUITING

Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.